In conclusion, combination treatment with anti-CTLA-4 mAb and MUC1 mRNA nanovaccine could increase the infiltration of CD8+ T cells into tumor sites and enhance anti-tumor cytotoxic T-lymphocyte activity by reducing immunosuppressive TME and inhibiting tumor-promoting STAT3 signaling pathway. The gene discussed is MUC1; the disease is neoplasm.